MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-23-2026
Integer Holdings Corporation Income Statement 2011-2026 | ITGR
Annual Income Statement Integer Holdings Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.98 B | 4.58 B | 3.34 B | 2.44 B | 2.77 B | 2.9 B | 2.86 B | 2.61 B | 1.63 B | 1.02 B | 1.26 B | 1.08 B | - | 639 M | 539 M |
Shares |
34.7 M | 33.6 M | 33.3 M | 33.1 M | 33 M | 32.8 M | 32.6 M | 32.6 M | 32.1 M | 26.4 M | 26 M | 25.3 M | - | 23.6 M | 23.6 M |
Historical Prices |
85.7 | 136 | 100 | 73.6 | 83.9 | 88.2 | 90.2 | 91 | 51 | 36.1 | 37.8 | 53.1 | 43.3 | 27.1 | 24.8 |
Net Income |
103 M | 120 M | 90.6 M | 66.4 M | 96.8 M | 77.3 M | 96.3 M | 168 M | 66.7 M | -7.59 M | 55.5 M | 36.3 M | - | -4.8 M | 33.1 M |
Revenue |
1.85 B | 1.72 B | 1.56 B | 1.33 B | 1.22 B | 1.07 B | 1.26 B | 1.22 B | 1.14 B | 800 M | 688 M | 664 M | - | 646 M | 569 M |
Cost of Revenue |
1.35 B | 1.26 B | 1.15 B | 986 M | 884 M | 788 M | 903 M | 852 M | 782 M | 738 M | 456 M | 445 M | - | 445 M | 388 M |
Gross Profit |
500 M | 459 M | 410 M | 346 M | 337 M | 286 M | 355 M | 363 M | 354 M | 235 M | 231 M | 219 M | - | 202 M | 180 M |
Operating Income |
221 M | 208 M | 163 M | 113 M | 136 M | 121 M | 158 M | 156 M | 126 M | 92.9 M | 75.7 M | 61.3 M | - | 25.8 M | 61.7 M |
Interest Expense |
-53.2 M | -3.52 M | -975 K | 899 K | 31.6 M | 38.2 M | 52.5 M | 99.3 M | 64 M | 68.3 M | 4.25 M | 11.3 M | - | 18.1 M | 16.9 M |
EBITDA |
352 M | 319 M | 262 M | 205 M | 217 M | 200 M | 244 M | 278 M | 228 M | 57.8 M | 113 M | 97.3 M | - | 72.2 M | 109 M |
Operating Expenses |
279 M | 251 M | 247 M | 233 M | 201 M | 165 M | 189 M | 173 M | 228 M | 222 M | 156 M | 158 M | - | 176 M | 119 M |
General and Administrative Expenses |
212 M | 185 M | 173 M | 158 M | 141 M | 109 M | 139 M | 116 M | 120 M | 92.8 M | 83.6 M | 82.3 M | - | 74.8 M | 72.5 M |
All numbers in USD currency
Quarterly Income Statement Integer Holdings Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
35.1 M | 35 M | 33.9 M | 33.5 M | 33.7 M | 33.6 M | 33.5 M | 33.3 M | 33.3 M | 33.3 M | 33.3 M | 33.2 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 33 M | 33 M | 33 M | 32.9 M | 32.9 M | 32.8 M | 32.8 M | 32.7 M | 32.7 M | 32.6 M | 32.5 M | 32.5 M | 32.2 M | 32 M | 31.9 M | 31.9 M | 31.6 M | 31.3 M | 31 M | 30.9 M | 30.8 M | 30.8 M | 30.7 M | 25.1 M | 25.5 M | 25.5 M | 25.3 M | 24.4 M | 24.9 M | 24.8 M | 24.6 M | - | 24 M | 23.9 M | 23.8 M | 23.7 M | 23.6 M | 23.6 M | 23.4 M | 23.4 M | 23.3 M | 23.2 M | 23.2 M |
Net Income |
39.7 M | 37 M | -22.5 M | - | 35.4 M | 31.2 M | 20.5 M | - | 27.3 M | 24 M | 13.1 M | - | 16.1 M | 20.8 M | 11.4 M | - | 22.1 M | 29.4 M | 21.5 M | - | 30.3 M | 389 K | 31.1 M | 11 M | 30.6 M | 33.1 M | 21.7 M | 19.2 M | -8.3 M | 23.1 M | 13.1 M | 54.7 M | 19.9 M | 9.56 M | 2.95 M | 7.93 M | 11.5 M | -770 K | -12.7 M | 14.2 M | 22 K | 9.28 M | 8.01 M | 9.78 M | 14 M | 12.3 M | 14.9 M | - | 11.1 M | 9.75 M | 5.66 M | -5.56 M | -7.56 M | 3.85 M | 4.47 M | 5.64 M | 6.99 M | 8.55 M | 11.9 M |
Revenue |
468 M | 476 M | 437 M | - | 431 M | 428 M | 408 M | - | 397 M | 400 M | 379 M | - | 343 M | 350 M | 311 M | - | 306 M | 312 M | 290 M | 269 M | 236 M | 240 M | 328 M | 326 M | 304 M | 314 M | 315 M | 303 M | 305 M | 314 M | 382 M | 390 M | 363 M | 281 M | 345 M | 360 M | 347 M | 348 M | 332 M | 170 M | 147 M | 175 M | 161 M | 177 M | 172 M | 172 M | 174 M | - | 168 M | 171 M | 148 M | 159 M | 161 M | 167 M | 159 M | 142 M | 132 M | 147 M | 149 M |
Cost of Revenue |
342 M | 347 M | 317 M | - | 315 M | 311 M | 300 M | - | 292 M | 294 M | 282 M | - | 256 M | 257 M | 229 M | - | 224 M | 223 M | 206 M | - | 178 M | 182 M | 232 M | - | 210 M | 217 M | 226 M | - | 213 M | 216 M | 209 M | - | 197 M | 192 M | 254 M | - | 249 M | 252 M | 241 M | - | 95 M | 117 M | 109 M | - | 114 M | 114 M | 117 M | - | 112 M | 114 M | 99.5 M | - | 110 M | 115 M | 112 M | - | 89.8 M | 99.9 M | 102 M |
Gross Profit |
126 M | 129 M | 120 M | - | 117 M | 117 M | 108 M | - | 105 M | 106 M | 96.7 M | - | 86.7 M | 92.9 M | 81.5 M | - | 81.9 M | 88.7 M | 84.5 M | 73.2 M | 57.9 M | 57.9 M | 96.7 M | 76 M | 93.4 M | 97 M | 88.6 M | 88.4 M | 91.9 M | 98.8 M | 83.5 M | 93.6 M | 89.2 M | 89.2 M | 82 M | 92.9 M | 97.9 M | 96 M | 91.5 M | 57.2 M | 51.6 M | 58 M | 52.4 M | 57.4 M | 58.1 M | 58.5 M | 57.6 M | - | 55.9 M | 57.3 M | 48.7 M | 51.9 M | 51 M | 51.9 M | 46.9 M | 44.7 M | 41.9 M | 46.6 M | 47.2 M |
Operating Income |
56.4 M | 59.3 M | 49.6 M | - | 58 M | 54.5 M | 38.7 M | - | 48.8 M | 41.6 M | 34.2 M | - | 29.3 M | 32.7 M | 22.5 M | - | 33.1 M | 39.4 M | 34.6 M | - | 39.8 M | 9.18 M | 44.1 M | - | 46.5 M | 49.3 M | 39.2 M | - | 41.5 M | 44.4 M | 30 M | - | 35.8 M | 36.1 M | 26.5 M | - | 36.9 M | 29.3 M | 11.1 M | - | 1.2 M | 13 M | 9.39 M | - | 16.2 M | 19.5 M | 22.5 M | - | 17 M | 17.1 M | 14.3 M | - | 2.13 M | 11.1 M | 11.2 M | - | 12.9 M | 18.3 M | 18 M |
Interest Expense |
-1.13 M | -3.98 M | -47.9 M | - | -916 K | 127 K | -1.01 M | - | -580 K | -359 K | 17.3 M | - | 10.7 M | 7.77 M | 5.97 M | - | 10.1 M | 7.53 M | 8.53 M | - | 9.37 M | 9.27 M | 10.4 M | - | 12.3 M | 13.6 M | 13.8 M | - | 54.5 M | 15.2 M | 15.6 M | - | 15.8 M | 15.1 M | 28.9 M | - | 27.9 M | 27.9 M | 27.6 M | - | 5.82 M | 1.21 M | 1.12 M | - | 1.05 M | 1.07 M | 1.08 M | - | 1.52 M | 1.44 M | 6.99 M | - | 4.4 M | 4.42 M | 4.36 M | - | 4.12 M | 4.4 M | 4.27 M |
EBITDA |
72.7 M | 75.5 M | 79.4 M | - | 71.6 M | 68.1 M | 64.9 M | - | 61.8 M | 54.7 M | 58.3 M | - | 41.4 M | 45 M | 45 M | - | 93.6 M | 49.7 M | 54.9 M | - | 98.8 M | 48.3 M | 63.6 M | - | 104 M | 87.9 M | 58.8 M | - | 110 M | 92.9 M | 56.4 M | - | 110 M | 85.5 M | 51.2 M | - | 104 M | 74.3 M | 33.5 M | - | 28.1 M | 31.2 M | 18.6 M | - | 44.1 M | 38.1 M | 31.8 M | - | 43.7 M | 35 M | 23.1 M | - | 36.2 M | 33.2 M | 22.3 M | - | 40 M | 36.3 M | 26.8 M |
Operating Expenses |
69.7 M | 69.8 M | 70.8 M | - | 58.6 M | 62.9 M | 69.6 M | - | 56.2 M | 64.2 M | 62.5 M | - | 57.5 M | 60.2 M | 59 M | - | 48.8 M | 49.4 M | 49.9 M | - | 18.2 M | 48.7 M | 52.6 M | - | 46.9 M | 47.6 M | 49.4 M | - | 50.5 M | 54.4 M | 53.5 M | - | 53.4 M | 53.1 M | 64.7 M | - | 61 M | 66.8 M | 80.3 M | - | 50.5 M | 44.9 M | 43 M | - | 41.9 M | 38.9 M | 35.1 M | - | 38.9 M | 40.2 M | 34.4 M | - | 48.8 M | 40.8 M | 35.7 M | - | 29 M | 28.3 M | 29.2 M |
General and Administrative Expenses |
50.5 M | 52.9 M | 51.2 M | - | 44.8 M | 46.5 M | 46.4 M | - | 41.4 M | 45.8 M | 41.9 M | - | 38.2 M | 41.8 M | 39.6 M | - | 34.3 M | 35.4 M | 35.5 M | - | 3.61 M | 33.9 M | 36.5 M | - | 32.9 M | 33.1 M | 35 M | - | 34.1 M | 36.8 M | 36.4 M | - | 35.1 M | 35.1 M | 39.5 M | - | 36.3 M | 37.6 M | 41.9 M | - | 22.3 M | 24.1 M | 22.6 M | - | 22.1 M | 21.9 M | 21.8 M | - | 21.6 M | 22.2 M | 20.1 M | - | 20.3 M | 20.7 M | 19 M | - | 17.8 M | 17.6 M | 18.6 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Integer Holdings Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Alphatec Holdings
ATEC
|
$ 11.94 | -1.73 % | $ 1.79 B |  USA |
 |
Butterfly Network
BFLY
|
$ 4.3 | 2.51 % | $ 910 M | USA |
 |
Bruker Corporation
BRKR
|
$ 36.29 | 4.1 % | $ 5.41 K | USA |
 |
ClearPoint Neuro
CLPT
|
$ 9.34 | -1.79 % | $ 264 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
- | - | $ 1.77 B | USA |
 |
Delcath Systems
DCTH
|
$ 8.95 | -1.65 % | $ 321 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | USA |
 |
Lianluo Smart Limited
LLIT
|
- | 24.59 % | $ 44.8 M |  China |
 |
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
FONAR Corporation
FONR
|
$ 18.35 | 0.05 % | $ 120 M | USA |
 |
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
- | -5.86 % | $ 30.6 M | USA |
 |
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | USA |
 |
Inogen
INGN
|
$ 6.26 | -2.92 % | $ 167 M | USA |
 |
LivaNova PLC
LIVN
|
$ 63.31 | 0.11 % | $ 3.45 B |  Britain |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
LENSAR
LNSR
|
$ 5.87 | -3.29 % | $ 67.6 M | USA |
 |
Medtronic PLC
MDT
|
$ 86.97 | -0.23 % | $ 112 B | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
IRIDEX Corporation
IRIX
|
$ 1.35 | -0.37 % | $ 21.8 M | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
Orthofix Medical
OFIX
|
$ 11.88 | 0.08 % | $ 470 M |  Curacao |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
- | -4.14 % | $ 702 M | USA |
 |
CHF Solutions, Inc.
CHFS
|
- | 1.15 % | $ 34.5 M | USA |
 |
AxoGen
AXGN
|
$ 32.34 | 1.86 % | $ 1.49 B | USA |
 |
Penumbra
PEN
|
$ 335.16 | -0.12 % | $ 13 B | USA |
 |
CONMED Corporation
CNMD
|
$ 36.38 | -0.68 % | $ 1.13 B | USA |
 |
Soliton, Inc.
SOLY
|
- | -1.42 % | $ 435 M | USA |
 |
Insulet Corporation
PODD
|
$ 224.56 | -1.11 % | $ 15.8 B | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
- | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
- | 0.03 % | $ 1.58 B |  Israel |
 |
Profound Medical Corp.
PROF
|
$ 5.22 | -3.33 % | $ 180 M |  Canada |
 |
Electromed
ELMD
|
$ 24.4 | -0.37 % | $ 206 M | USA |
 |
Misonix, Inc.
MSON
|
- | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.75 | -4.82 % | $ 160 M | USA |
 |
Intersect ENT, Inc.
XENT
|
- | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 0.68 | 0.95 % | $ 37 M | USA |
 |
Aethlon Medical
AEMD
|
$ 2.24 | -2.61 % | $ 3.5 M | USA |
 |
Sintx Technologies
SINT
|
$ 2.58 | 1.18 % | $ 7.16 M | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
AdaptHealth Corp.
AHCO
|
$ 10.96 | 5.68 % | $ 1.48 B | USA |
 |
Stryker Corporation
SYK
|
$ 329.09 | -1.05 % | $ 126 B | USA |
 |
Myomo
MYO
|
$ 0.72 | 2.1 % | $ 30.1 M | USA |
 |
Tactile Systems Technology
TCMD
|
$ 26.28 | -0.87 % | $ 601 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 100.0 | 0.81 % | $ 1.27 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 2.38 | -2.25 % | $ 140 M | Israel |